Titre
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Garweg, J.G.
Auteure/Auteur
Blum, C.A.
Auteure/Auteur
Copt, R.P.
Auteure/Auteur
Eandi, C.M.
Auteure/Auteur
Hatz, K.
Auteure/Auteur
Prünte, C.F.
Auteure/Auteur
Seelig, E.
Auteure/Auteur
Somfai, G.M.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2193-8245
Statut éditorial
Publié
Date de publication
2023-04
Volume
12
Numéro
2
Première page
639
Dernière page/numéro d’article
655
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related vision loss. However, the need for regular injections places a significant burden on patients, caregivers, and the healthcare system and improvements in vision may not be maintained long term. As a result of its drying potency and duration of action, brolucizumab, an intravitreal anti-VEGF therapy approved for the treatment of nAMD and DME, could decrease injection frequency for patients and provide an efficacious treatment; however, balancing its benefits and risks can be challenging. There have been reports of intraocular inflammation (IOI) in patients treated with brolucizumab, which, if left untreated, may result in severe vision loss. Recent evidence, however, indicates that early recognition of IOI and prompt and aggressive systemic corticosteroid treatment in response to posterior segment involvement can lead to favorable outcomes in these relatively rare but severe cases. A series of consensus meetings were conducted in 2022 between Swiss medical retina experts and diabetologists, discussing the current data for brolucizumab and exploring various challenges to its use, including the associated risk of IOI. The outcome is a collation of practical insights and guidance for ophthalmologists on the use of brolucizumab in patients with nAMD and DME, including patient selection and assessment, treatment regimen and monitoring, and the recognition and management of adverse events.
PID Serval
serval:BIB_A8A163A2B7E5
PMID
Open Access
Oui
Date de création
2023-01-23T10:37:43.428Z
Date de création dans IRIS
2025-05-21T01:24:48Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
36633780_BIB_A8A163A2B7E5.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc/4.0
Taille
947.63 KB
Format
Adobe PDF
PID Serval
serval:BIB_A8A163A2B7E5.P002
URN
urn:nbn:ch:serval-BIB_A8A163A2B7E55
Somme de contrôle
(MD5):e77c6b4c486daad35d1b634ff939d00a